Alamar Biosciences, Inc. (ALMR) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
Alamar Biosciences, Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Proceeds from issuance of common stock in connection with IPO, net of underwriting costs → financing reconciliation: $204,542,000.00Proceeds from issuance of common stock upon exercise of stock options → financing reconciliation: $1,231,000.00financing reconciliation → Net cash from financing activities: $201,841,000.00financing reconciliation → Payment of third-party IPO costs: $3,932,000.00Net cash used in investing activities → investing reconciliation: $120,796,000.00investing reconciliation → Purchases of short-term investments: $117,045,000.00investing reconciliation → Purchases of property and equipment: $3,642,000.00investing reconciliation → Capitalized software development costs: $109,000.00Net cash used in operating activities → operating reconciliation: $11,322,000.00Accounts payable → operating reconciliation: $6,319,000.00Stock-based compensation → operating reconciliation: $3,280,000.00Loss on remeasurement of convertible notes → operating reconciliation: $1,377,000.00Depreciation and amortization expense → operating reconciliation: $1,134,000.00Non-cash operating lease costs → operating reconciliation: $684,000.00Operating lease liabilities → operating reconciliation: $184,000.00Provision for expected credit losses → operating reconciliation: $135,000.00Unrealized foreign exchange loss (gain) → operating reconciliation: $80,000.00Amortization of debt issuance costs → operating reconciliation: $70,000.00Change in fair value of warrant liabilities → operating reconciliation: $33,000.00operating reconciliation → Net loss: $13,199,000.00operating reconciliation → Inventory: $5,725,000.00operating reconciliation → Accrued expenses and other liabilities: $3,206,000.00operating reconciliation → Accounts receivable: $967,000.00operating reconciliation → Prepaid expenses and other current assets: $900,000.00operating reconciliation → Other noncurrent assets: $484,000.00operating reconciliation → Accretion and amortization of premiums and discounts on investments, net: $137,000.00Exchange-rate effect → Cash sources and uses: $7,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $69,493,000.00Net cash from financing activities → Cash sources and uses: $201,841,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $139,223,000.00Cash sources and uses → Net cash used in investing activities: $120,796,000.00Cash sources and uses → Net cash used in operating activities: $11,322,000.00Net loss: -$13,199,000.00Net loss−$13.20 MDepreciation and amortization expense: $1,134,000.00Depreciation & amortization+$1.13 MStock-based compensation: $3,280,000.00Stock-based compensation+$3.28 MAccretion and amortization of premiums and discounts on investments, net: -$137,000.00Investment discount & premium−$137.00 KLoss on remeasurement of convertible notes: $1,377,000.00Convertible note remeasure loss+$1.38 MConvertible note issuance costs included in net loss: $0.00Unrealized foreign exchange loss (gain): $80,000.00Unrealized FX gain & loss+$80.00 KNon-cash operating lease costs: $684,000.00Operating lease amortization+$684.00 KAmortization of debt issuance costs: $70,000.00Debt issuance cost amortization+$70.00 KProvision for expected credit losses: $135,000.00Credit loss provision+$135.00 KChange in fair value of warrant liabilities: $33,000.00Warrant fair value+$33.00 KAccounts receivable: -$967,000.00Accounts receivable−$967.00 KInventory: -$5,725,000.00Inventories−$5.73 MPrepaid expenses and other current assets: -$900,000.00Prepaid & other assets−$900.00 KOther noncurrent assets: -$484,000.00Other noncurrent assets−$484.00 KAccounts payable: $6,319,000.00Accounts payable+$6.32 MOperating lease liabilities: $184,000.00Operating lease liabilities+$184.00 KAccrued expenses and other liabilities: -$3,206,000.00Other payables & accruals−$3.21 MNet cash used in operating activities: -$11,322,000.00. Cash required to fund net payments.Operating cash−$11.32 Moperating reconciliation: $24,618,000.00Proceeds from issuance of common stock in connection with IPO, net of underwriting costs: $204,542,000.00Common stock issued+$204.54 MProceeds from issuance of convertible notes: $0.00Payment of third-party debt issuance costs: $0.00Proceeds from issuance of common stock upon exercise of stock options: $1,231,000.00Stock option exercises+$1.23 MPayment of third-party IPO costs: -$3,932,000.00Stock issuance costs−$3.93 MNet cash from financing activities: $201,841,000.00Financing cash+$201.84 Mfinancing reconciliation: $205,773,000.00Purchases of short-term investments: -$117,045,000.00Short-term investment purchases−$117.05 MPurchases of property and equipment: -$3,642,000.00PP&E purchases−$3.64 MCapitalized software development costs: -$109,000.00Software development costs−$109.00 KNet cash used in investing activities: -$120,796,000.00. Cash required to fund net payments.Investing cash−$120.80 Minvesting reconciliation: $120,796,000.00Cash sources and uses: $271,341,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $69,493,000.00Beginning cash$69.49 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $139,223,000.00Ending cash$139.22 MExchange-rate effect: $7,000.00FX effect+$7.00 KCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$13.20M + net operating adjustments $1.88M = operating cash −$11.32MFree cash flow−$14.96 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$69.73 MEnding cash − beginning cash
Chart details

Alamar Biosciences, Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
69,493,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
negative 11,322,000 US dollars. Net cash used.
Net loss
negative 13,199,000 US dollars
Depreciation and amortization expense
1,134,000 US dollars
Stock-based compensation
3,280,000 US dollars
Accretion and amortization of premiums and discounts on investments, net
negative 137,000 US dollars
Loss on remeasurement of convertible notes
1,377,000 US dollars
Convertible note issuance costs included in net loss
0 US dollars
Unrealized foreign exchange loss (gain)
80,000 US dollars
Non-cash operating lease costs
684,000 US dollars
Amortization of debt issuance costs
70,000 US dollars
Provision for expected credit losses
135,000 US dollars
Change in fair value of warrant liabilities
33,000 US dollars
Accounts receivable
negative 967,000 US dollars
Inventory
negative 5,725,000 US dollars
Prepaid expenses and other current assets
negative 900,000 US dollars
Other noncurrent assets
negative 484,000 US dollars
Accounts payable
6,319,000 US dollars
Operating lease liabilities
184,000 US dollars
Accrued expenses and other liabilities
negative 3,206,000 US dollars
Investing activities
negative 120,796,000 US dollars. Net cash used.
Purchases of short-term investments
negative 117,045,000 US dollars
Purchases of property and equipment
negative 3,642,000 US dollars
Capitalized software development costs
negative 109,000 US dollars
Financing activities
201,841,000 US dollars. Net cash provided.
Proceeds from issuance of common stock in connection with IPO, net of underwriting costs
204,542,000 US dollars
Proceeds from issuance of convertible notes
0 US dollars
Payment of third-party debt issuance costs
0 US dollars
Proceeds from issuance of common stock upon exercise of stock options
1,231,000 US dollars
Payment of third-party IPO costs
negative 3,932,000 US dollars
Operating adjustment reconciliation
24,618,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
205,773,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
120,796,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
7,000 US dollars
Ending cash on Jun 30, 2026
139,223,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
271,341,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
69,730,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 11,322,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
3,642,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 14,964,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$13.20M + net operating adjustments $1.88M = operating cash −$11.32M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 11,322,000 US dollars minus 3,642,000 US dollars equals negative 14,964,000 US dollars.
Alamar Biosciences, Inc. (ALMR) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!